Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Phenotype of the Most Common “Slow Acetylator” Arylamine N-Acetyltransferase 1 Genetic Variant (NAT1*14B) Is Substrate-Dependent

Lori M. Millner, Mark A. Doll, Jian Cai, J. Christopher States and David W. Hein
Drug Metabolism and Disposition January 2012, 40 (1) 198-204; DOI: https://doi.org/10.1124/dmd.111.041855
Lori M. Millner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark A. Doll
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jian Cai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Christopher States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Hein
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Human arylamine N-acetyltransferase 1 (NAT1) is a phase II cytosolic enzyme responsible for the activation or deactivation of many arylamine compounds including pharmaceuticals and environmental carcinogens. NAT1 is highly polymorphic and has been associated with altered risk toward many cancers. NAT1*14B is characterized by a single nucleotide polymorphism in the coding region (rs4986782; 560G>A; R187Q). NAT1*14B is associated with higher frequency of smoking-induced lung cancer and is the most common “slow acetylator” arylamine NAT1 genetic variant. Previous studies have reported decreased N- and O-acetylation capacity and increased proteasomal degradation of NAT1 14B compared with the referent, NAT1 4. The current study is the first to investigate NAT1*14B expression using constructs that completely mimic NAT1 mRNA by including the 5′- and 3′-untranslated regions, together with the open reading frame of the referent, NAT1*4, or variant, NAT1*14B. Our results show that NAT1 14B is not simply associated with “slow acetylation.” NAT1 14B-catalyzed acetylation phenotype is substrate-dependent, and NAT1 14B exhibits higher N- and O-acetylation catalytic efficiency as well as DNA adducts after exposure to the human carcinogen 4-aminobiphenyl.

Footnotes

  • This work was supported by the National Institutes of Health National Cancer Institute [Grant R01-CA034627]; the National Institutes of Health National Institute for Environmental Health Sciences [Grants T32-ES011564, P30-ES014443]; and the Department of Defense Breast Cancer Research Program [Grant BC083107].

  • Portions of this work constitute partial fulfillment of the requirements for the degree of Doctor of Philosophy in pharmacology and toxicology: Millner LM (2011) Functional Analysis of N-Acetyltransferase (NAT1*14B and NAT1*10) in Complete NATb and NATa mRNA. Doctoral dissertation, University of Louisville, Louisville, KY.

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

    http://dx.doi.org/10.1124/dmd.111.041855.

  • ABBREVIATIONS:

    NAT1
    N-acetyltransferase 1
    CoASAc
    acetyl CoA
    PABA
    p-aminobenzoic acid
    UTR
    untranslated region
    ABP
    4-aminobiphenyl
    HPLC
    high-performance liquid chromatography
    N-OH-ABP
    N-hydroxy-4-aminobiphenyl
    ORF
    open reading frame
    CHO
    Chinese hamster ovary
    FRT
    Flp recombination target
    α-MEM
    α-modified minimal essential medium
    ACN
    acetonitrile
    dG
    deoxyguanosine
    PBS
    phosphate-buffered saline.

  • Received July 20, 2011.
  • Accepted October 18, 2011.
  • Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 40 (1)
Drug Metabolism and Disposition
Vol. 40, Issue 1
1 Jan 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Phenotype of the Most Common “Slow Acetylator” Arylamine N-Acetyltransferase 1 Genetic Variant (NAT1*14B) Is Substrate-Dependent
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
Citation Tools
Research ArticleArticle

NAT1*14B PHENOTYPE IS SUBSTRATE-DEPENDENT

Lori M. Millner, Mark A. Doll, Jian Cai, J. Christopher States and David W. Hein
Drug Metabolism and Disposition January 1, 2012, 40 (1) 198-204; DOI: https://doi.org/10.1124/dmd.111.041855

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

NAT1*14B PHENOTYPE IS SUBSTRATE-DEPENDENT

Lori M. Millner, Mark A. Doll, Jian Cai, J. Christopher States and David W. Hein
Drug Metabolism and Disposition January 1, 2012, 40 (1) 198-204; DOI: https://doi.org/10.1124/dmd.111.041855
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Abundant expression of OCT2, MATE1, OAT1, OAT3, PEPT2, BCRP, MDR1 and xCT transporters in blood-arachnoid barrier of pig, and polarized localizations at CSF- and blood-facing plasma membranes
  • Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-mediated Uptake
  • Human Cytochrome P450 1A1 Adapts Active Site for Atypical Nonplanar Substrate
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics